Expression of cyclin-dependent kinase inhibitor p27kip1 in malignant lymphomas

Journal of Korean Medical Science

Volumn 15, Issue 4, 2000, Pages 399-406

  Oh, Young Ha ^b   Park, Chan Kum ^a  

^a Hanyang University   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

Lymphoma; p27kip1; Prognostic Factor

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; KI 67 ANTIGEN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL CYCLE; CELL DIVISION; CHEMISTRY; CHILD; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; LIFE TABLE; MALE; MIDDLE AGED; MORTALITY; NONHODGKIN LYMPHOMA; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; LIFE TABLES; LYMPHOMA, NON-HODGKIN; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 0034243238     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2000.15.4.399     Document Type: Article

References (33)

1. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-7.
2. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-63.
3. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994; 8: 2939-52.
4. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, Wei N. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995; 6: 387-400.
5. Kip-1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9-22.
6. Kip-1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
7. Kip1 accumulation during the cell cycle. Science 1996; 271: 1861-4.
8. Kip1) of cyclin-dependent kinase 4 activation. Cell 1994; 79: 487-96.
9. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 1998; 92: 770-7.
10. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-82.
11. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227-30.
12. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997; 57: 3381-5.
13. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3: 231-4.
14. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T. p27 expression and gastric carcinoma. Nat Med 1997; 3: 593.
15. Tan P, Cady B, Wanner M, Worland P, Cukor B, MagiGalluzzi C, Lavin P, Draetta G, Pagano M, Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997; 57: 1259-63.
16. Kipi is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 1997; 88: 625-9.
17. Iida H, Towatari M, Tanimoto M, Morishita Y, Kodera Y, Saito H. Overexpression of cyclin E in acute myelogenous leukemia. Blood 1997; 90: 3707-13.
18. Kip-1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3: 222-5.
19. Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol 1998; 153: 175-82.
20. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
21. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 1996; 271: 499-502.
22. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372: 570-3.
23. Kip-1. Cell 1996; 85: 721-32.
24. (Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85: 707-20.
25. (Kip1)-deficient mice. Cell 1996; 85: 733-44.
26. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841-54.
27. Kip1. Genes Dev 1997; 11: 1464-78.
28. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-5.
29. Kip-1, to regions involved in human cancer. Cancer Res 1995; 55: 1199-205.
30. Kip-1 in human malignancies. Cancer Res 1995; 55: 2266-9.
31. Kip-1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995; 55: 1206-10.
32. Kip-1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995; 55: 1211-4.
33. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Nat Acad Sci USA 1997; 94: 6380-5.